Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07481110

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.

It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Béni Messous, Algiers, Algeria

Loading trial locations.

About this study

This is a non-interventional, observational, descriptive, cross-sectional clinical study with both prospective and retrospective data collection. It aims to describe the demographic, epidemiological, clinical, and outcome characteristics of approximately 1,000 patients with histologically confirmed gastric cancer in Algeria, and to analyze diagnostic and treatment practices.

Data will be collected from medical records and brief patient interviews (≈30 minutes). All information will be anonymized and used exclusively for research purposes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 19 years and older
  • Histologically confirmed diagnosis of gastric cancer
  • Patients followed in the participating oncology departments
  • Informed consent obtained

Non Inclusion Criteria:

  • Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.).
  • Secondary gastric tumors
  • Participation in an interventional study

Treatment and study plan

Primary outcomes

  1. Demographic characteristics of patients with gastric cancer in Algeria

    Time frame: At Baseline ( Initial visit )

    The patient's demographic profile will include age (years) and sex. Body Mass Index (BMI) will be calculated using weight (kg) and height (m) according to the formula BMI = weight / height² (kg/m²).

  2. Sociological characteristics of patients with gastric cancer in Algeria

    Time frame: At Baseline ( Initial visit )

    The patient's sociological profile will be described as a composite variable : Education level (primary, secondary, university, other), Profession (employed, unemployed, retired, student, other), Place of residence (current residence; urban or rural), Origin (wilaya of birth/origin)

  3. Epidemiological characteristics of patients with gastric cancer in Algeria.

    Time frame: At Baseline (Initial Visit)

    Frequency (%) of epidemiological risk factors including family history of cancer, Helicobacter pylori infection, smoking status, alcohol consumption, dietary habits, and exposure to chemical substances.

  4. Clinical characteristics of patients with gastric cancer in Algeria.

    Time frame: At Basline ( Initial Visit)

    Distribution of patients according to initial symptoms, tumor localization, histological characteristics, biomarker expression, presence of metastases, and tumor stage according to the AJCC classification.

  5. Evolutionary characteristics of patients with gastric cancer.

    Time frame: At Baseline ( Initial Visit)

    Distribution of treatment modalities including surgery (palliative or curative) and chemotherapy (adjuvant or treatment lines), as well as treatment response, complications, disease-free survival (DFS), and duration of response.

Secondary outcomes

  1. Diagnostic modalities in patients with gastric cancer in Algeria

    Time frame: At Basline (Initial Visit)

    Proportion (%) of patients diagnosed using endoscopy, biopsy, or imaging, and median time to diagnosis (days) defined as the interval between first reported symptom and confirmed diagnosis.

  2. Therapeutic management modalities

    Time frame: At Baseline (Initial Visit)

    Proportion (%) of patients receiving surgery, chemotherapy, targeted therapy, immunotherapy, or palliative care, median time from confirmed diagnosis to initiation of first treatment (days), and proportion of patients with documented post-treatment follow-up.

Sponsors and collaborators

Lead sponsor

Société Algérienne de Formation et Recherche en Oncologie

Other

Collaborators

  • Bristol-Myers Squibb
  • ES Clinical Research

Registry information

Acronym: ECLIPSE-CG

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 18, 2026
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.